Novartis challenges Pfizer with strong breast cancer drug data

COPENHAGEN (Reuters) - An experimental Novartis pill given with an older drug kept advanced breast cancer in check far longer than standard treatment alone, putting it on track to challenge Pfizer's blockbuster Ibrance, data showed on Saturday.